# Andrew Rechenberg

**Senior Economist, Coalition for a Prosperous America**

Andrew Rechenberg is a Senior Economist at the Coalition for a Prosperous America (CPA), where he leads research on pharmaceutical supply chains, U.S. trade policy, and industrial strategy. His work examines American dependence on China and India for generic drugs, antibiotics, and the ingredients used to make them.

Mr. Rechenberg testified before the U.S. Senate Special Committee on Aging on October 8, 2025, at the hearing "Bad Medicine: Closing Loopholes that Kill American Patients," and the Committee highlighted his testimony on the decline of domestic drug production and risks with foreign pharmaceutical reliance. He is the author of several CPA reports on the drug supply chain, including "The Hollowing Out of America's Medicine Cabinet," "Foreign Control of Antibiotic Supply: U.S. and European Import Reliance and Systemic Vulnerabilities," and "The Economic Case for Generic Drug Reshoring."

Before joining CPA, he served as an International Economist at the U.S. Department of Commerce's International Trade Administration, where he worked on aerospace and defense trade and supported national security reviews of foreign investment under the Committee on Foreign Investment in the United States (CFIUS), and as an analyst at the Defense Intelligence Agency. He also worked with the U.S. Mission to the European Union in Brussels. In the private sector, he led trade compliance and tariff analysis at Stanley Black & Decker and conducted macroeconomic forecasting at Moody's Analytics.

He holds a Master of International Affairs and bachelor's degrees in economics and political science from Pennsylvania State University.